1. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28 (16): 2784–2795. doi: 10.1200/JCO.2009.25.6529.
2. Thorpe SM, Rose C, Rasmussen BB et al. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 1987; 47 (22): 6126–6133.
3. Nomura Y, Miura S, Koyama H et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. A univariate and multivariate analysis of 3089 japanese patients with breast cancer from the study group for the japanese breast cancer society on hormone receptors and prognosis in breast cancer. Cancer 1992; 69 (1): 153–164.
4. Milani A, Geuna E, Mittica G et al. Overcoming endocrine resistance in metastatic breast cancer. Current evidence and future directions. World J Clin Oncol 2014; 5 (5): 990–1001. doi: 10.5306/wjco.v5.i5.990.
5. Sherr CJ. Cancer cell cycles. Science 1996; 274 (5293): 1672–1677.
6. Shapiro GI. Cyclin-dependent kinase pathway as targets for cancer treatment. J Clin Oncol 2006; 24 (11): 1770–1783. doi: 10.1200/JCO.2005.03.7689.
7. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9 (11): 785–797. doi: 10.1038/nrc2696.
8. Johnson J, Thijssen B, McDermott U et al. Targeting the RB-E2F pathway in breast cancer. Oncogene 2016; 35 (37): 4829–4835. doi: 10.1038/onc.2016.32.
9. Asghar U, Witkiewicz AK, Turner NC et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015; 14 (2): 130–146. doi: 10.1038/nrd4504.
10. Shah AN, Cristofanilli M. The growing role of CDK4/6 inhibitors in treating hormone receptor-positive advanced breast cancer. Curr Treat Options Oncol 2017; 18 (1): 6. doi: 10.1007/s11864-017-0443-7.
11. Sablin MP, Ricci F, Loirat D et al. Cell cycle inhibitors in endocrine receptor positive breast cancer. Bull Cancer 2017; 104 (2): 114–122. doi: 10.1016/j.bulcan.2016.12.005.
12. Finn RS, Crown JP, Lang I et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16 (1): 25–35. doi: 10.1016/S1470-2045 (14) 71159-3.
13. Finn RS, Martin M, Rugo HS et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375 (20): 1925–1936. doi: 10.1056/NEJMoa1607303.
14. Cristofanilli M, Turner NC, Bondarenko I et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17 (4): 425–439. doi: 10.1016/S1470-2045 (15) 00613-0.
15. Hortobagyi GN, Stemmer SM, Burris HA et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375 (18): 1738–1748. doi: 10.1056/NEJMoa1609709.
16. Sledge GW, Toi M, Neven P et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017; 35 (25): 2875–2884. doi: 10.1200/JCO.2017.73.7585.
17. Goetz MP, Toi M, Campone M et al: MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017; 35: 3628–3646. doi: 10.1200/JCO.2017.75.6155.
18. NCCN. [online]. Available from: https: //www.nccn.org.